论文部分内容阅读
Gut杂志上的一份报告指出:大多数结直肠肿瘤患者术前血清中都能发现KRAS2突变体,但是在手术后该突变体再被检出则有力地预示着疾病的复发。 荷兰Maastricht大学医院Dr.B. M. Ryan及其同事,分别评价了78名术前结直肠肿瘤患者和94名已接受肿瘤切除手术的病人(连续三年内每月三次对这94名患者进行采血检查),对他们肿瘤和血清样本中第12、13号密码子的KRAS2突变体情况进行了分析。 他们发现,在78名术前患者中,41人(53％)的肿瘤样本和32人(41％)的血清样本中检出KRAS2突变体。41名在肿瘤中检出有KRAS2突变体患者中的31名(76％)病人血清中也发现了突变体。
A report from Gut magazine found that most KRAS2 mutants were found in preoperative sera from patients with colorectal neoplasms, but their reappearance after surgery was a strong predictor of disease recurrence. Dr.BM Ryan and colleagues from Maastricht University Hospital in the Netherlands evaluated 78 patients with preoperative colorectal cancer and 94 patients who had undergone tumor resection (blood tests were performed on these 94 patients three times per month for three consecutive years) The KRAS2 mutants of codons 12 and 13 in their tumor and serum samples were analyzed. They found that in 78 preoperative patients, KRAS2 mutants were detected in 41 (53%) of the tumor samples and 32 (41%) of the serum samples. Mutants were also found in the sera of 31 (31%) of the 41 patients with KRAS2 mutations detected in the tumor.